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Abstract: An essential component of the human diet, L-tryptophan is critical in a number of metabolic functions and has 
been widely used in numerous research and clinical trials. This review provides a brief overview of the role of L-tryptophan 
in protein synthesis and a number of other metabolic functions. With emphasis on L-tryptophan’s role in synthesis of brain 
serotonin, details are provided on the research uses of L-tryptophan, particularly L-tryptophan depletion, and on clinical 
trials that have been conducted using L-tryptophan supplementation. The ability to change the rates of serotonin synthesis 
in the brain by manipulating concentrations of serum tryptophan is the foundation of much research. As the sole precursor 
of serotonin, experimental research has shown that L-tryptophan’s role in brain serotonin synthesis is an important factor 
involved in mood, behavior, and cognition. Furthermore, clinical trials have provided some initial evidence of L-tryptophan’s 
efﬁ  cacy for treatment of psychiatric disorders, particularly when used in combination with other therapeutic agents.
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Introduction
Hopkins and Cole
1 discovered tryptophan in the early 1900s after isolating it from casein protein, and 
Ellinger and Flamand
2 determined its molecular structure a short time later. L-tryptophan (i.e. tryptophan) 
is one of eight essential amino acids (i.e. amino acids that cannot be synthesized in the human body and 
must be supplied by the diet).
3–5 For all amino acids, including L-tryptophan, only the L isomer is used 
in protein synthesis
6 and can pass across the blood-brain barrier.
7,8 In humans, tryptophan has relatively 
low tissue storage
9 and the overall tryptophan concentration in the body is the lowest among all amino 
acids,
10,11 although only small amounts are necessary for general healthy nutrition.
5,12 While typical 
intake for many individuals is approximately 900 to 1000 mg daily, the recommended daily allowance 
for adults is estimated to be between 250 mg/day
5,12,13 and 425 mg/day,
4,14,15 which translates to a dietary 
intake of 3.5 to 6.0 mg/kg of body weight per day. Some common sources of tryptophan are oats, bananas, 
dried prunes, milk, tuna ﬁ  sh, cheese, bread, chicken, turkey, peanuts, and chocolate (see Table 1).
11,16
Tryptophan was ﬁ  rst synthesized in 1949, but by the early 1980’s chemical synthesis of tryptophan 
was replaced with fermentation procedures that greatly increased obtainable yields, making tryptophan 
supplements more available.
17 Shortly thereafter, from approximately 1988 to 1989, there was an out-
break of eosinophilia-myalgia syndrome (EMS) that was linked to consumption of synthetic tryptophan. 
Upon investigation, the source of the outbreak was traced to a single manufacturer, the Showa Denka 
Company of Japan, and the cause was determined to be a change in their processes of tryptophan 
synthesis.
18–23 The EMS outbreak prompted the United States Food and Drug Administration (FDA) to 
place a ban on all over-the-counter uses of tryptophan supplements, allowing only limited regulated 
use of tryptophan produced by United States manufacturers. Following the identiﬁ  cation of the source 
of the outbreak, the ban was lifted in 2001.
23 Since then, numerous research and clinical trials have 
been conducted without incident.
7,24–34
The purpose of the following review is to provide an overview of tryptophan as an essential amino 
acid, with emphasis on tryptophan’s role in the synthesis of brain serotonin. The importance of tryp-
tophan for a multitude of metabolic functions, and information on the research methodologies and 46
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uses, as well as therapeutic uses of tryptophan are 
discussed.
Metabolic processes
Protein synthesis
The principal role of tryptophan in the human body 
is as a constituent of protein synthesis. Because 
tryptophan is found in the lowest concentrations 
among the amino acids, it is relatively less available 
and is thought to play a rate-limiting role during 
protein synthesis.
3,5 Tryptophan is also the precur-
sor of two important metabolic pathways, kynurenine 
synthesis
5,12,13 and serotonin synthesis.
5,7,35–37
Kynurenine synthesis
After protein synthesis, the second most prevalent 
metabolic pathway of tryptophan is for the 
synthesis of kynurenine, which accounts for 
approximately 90% of tryptophan catabolism.
5,12, 37 
Kynurenine is a key component in the synthesis of 
a number of metabolites, but most importantly, it 
is the precursor of kynurenic and quinolinic acids. 
Each of these metabolites has the potential to affect 
other neurotransmitters; speciﬁ  cally kynurenic acid 
is a glutamate receptor antagonist, while quinolinic 
acid is a glutamate receptor agonist.
39 Among other 
pathways, kynurenine is known to be involved in 
acting as an ultra violet (UV) ﬁ  lter which protects 
the retina of the eye from UV damage.
40,41 The 
effectiveness of this protection deteriorates with 
age, contributing to the normal changes in color-
ation and ﬂ  uorescence of the lens that interfere 
with visual function and may, in some individuals, 
play a role in cataract formation.
Serotonin synthesis
It is estimated that 95% of mammalian serotonin 
is found within the gastrointestinal tract,
42 and only 
3% of dietary tryptophan is used for serotonin 
synthesis throughout the body.
43 Nevertheless, 
serotonin synthesis is one of the most important 
tryptophan pathways and a topic of intense 
Table 1. The L-tryptophan and competing amino acids (CAAs) found in common foods. The L-tryptophan/CAA 
ratio represents the relative availability of plasma L-tryptophan for crossing the blood-brain barrier and is thought 
to be the best indicator of brain serotonin synthesis.
L-tryptophan* 
(mg) 
Sum of CAAs**
(mg)
Ratio
Turkey, Skinless, Boneless, Light Meat (per pound, raw) 410 9,525 0.043
Chicken, Skinless, Boneless, Light Meat (per pound, raw) 238 5,122 0.046
Turkey, Skinless, Boneless, Dark Meat (per pound, raw) 303 7,036 0.043
Chicken, Skinless, Boneless, Dark Meat (per pound, raw) 256 5,492 0.047
Whole Milk (per quart) 732 8,989 0.081
2% Milk (per quart) 551 12,516 0.044
Wheat Bread (per slice) 19 317 0.060
White Bread (per slice) 22 439 0.050
Semisweet Chocolate (per ounce) 18 294 0.061
Sweet Chocolate (per ounce) 16 270 0.059
Canned Tuna (per ounce) 472 10,591 0.045
Cheddar Cheese (per ounce) 91 2,298 0.040
Peanuts (per ounce) 65 1,574 0.041
Oats for Oatmeal (per cup) 147 2,617 0.056
Dried Prune (one) 2 27 0.074
Banana (one medium) 11 237 0.046
Apple (one medium) 2 70 0.029
*e.g. The recommended daily allowance for a 79 kg (175 lb) adult is 278 to 476 mg.
**  CAAs = Isoleucine, Leucine, Phenylalanine, Tyrosine, and Valine, the ﬁ  ve large neutral amino acids typically included in the tryptophan/CAA ratio.47
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research. It is estimated that only 1% of dietary 
tryptophan is used for serotonin synthesis in the 
brain,
12,44 but despite the relatively low concentra-
tion of brain serotonin compared to that in the rest 
of the body, it has a broad impact as a neurotrans-
mitter and neuromodulator and has been implicated 
in numerous psychiatric conditions and psycho-
logical processes.
Tryptamine synthesis
In addition to tryptophan’s three major activities 
of protein, kynurenine, and serotonin synthesis, 
tryptamine is another biologically active compound 
that is derived from tryptophan. The immediate 
decarboxylation of tryptophan results in the 
synthesis of trace amounts of tryptamine (i.e. ng/g), 
which is an important neuromodulator of serotonin.
45 
Numerous animal studies have indicated that 
tryptamine acts as a control for the balance between 
excitatory and inhibitory functions of serotonin, 
and in other instances, tryptamine acts as a neu-
rotransmitter with speciﬁ  c receptors that are inde-
pendent of serotonin function.
45
Melatonin synthesis
Melatonin is a hormone produced in the tryptophan/
serotonin pathway,
46,47 which regulates diurnal 
rhythms and influences the reproductive and 
immune systems,
47 as well as digestive processes 
and gastrointestinal motility.
48 Melatonin synthesis 
is regulated by the blue light spectrum (i.e. 446 to 
477 nm) in both artiﬁ  cial and sun light.
49–51 During 
periods of darkness, it is actively secreted from the 
pineal gland to induce neural and endocrine effects 
that regulate circadian rhythms of behavior, 
physiology, and sleep patterns.
52
NAD/NADP synthesis
Tryptophan also plays a role as a substrate for 
synthesis of the coenzymes nicotinamide ade-
nine dinucleotide (NAD) and NAD phosphate 
(NADP).
5,12,53,54 NAD and NADP are coenzymes 
essential for electron transfer reactions (i.e. redox 
reactions) in all living cells. These enzymes can 
be synthesized de novo from ingested tryptophan, 
or from ingestion of niacin (i.e. vitamin B3).
Niacin synthesis
Interestingly, tryptophan can act as a substrate for 
niacin synthesis
5,12 through the kynurenine/
quinolinic acid pathway. However, this is a less 
efﬁ  cient use of tryptophan since approximately 
60 mg of tryptophan are necessary to generate a 
single milligram of niacin.
5,11,55 The recommended 
daily allowance of niacin is only 16 mg/day for 
men and 14 mg/day for women.
56 For adults, in 
the United States, the median intake of niacin from 
food is approximately 41 mg/day for men and 
28 mg/day for women,
57 leaving little need for 
additional synthesis from tryptophan.
Other metabolic functions
Tryptophan also exerts effects on other neurotrans-
mitters and CNS compounds. Dopamine, norepi-
nephrine, and beta-endorphin have been shown to 
increase following oral dosing of tryptophan.
 42,58–61 
Through serotonin synthesis, tryptophan is 
also thought to be involved in modulation of the 
endocrine system and cortisol,
60,62 as well as 
prolactin and growth hormone.
63,64
In summary, while tryptophan is found in the 
smallest concentrations of the 20 amino acids in 
the human body,
9–11 it has wide-ranging effects and 
is a critical component of a multitude of essential 
metabolic functions. While there are three primary 
functions of tryptophan (i.e. protein, serotonin, and 
kynurenine synthesis), the focus of the remainder 
of this discussion is on tryptophan’s role in the 
synthesis of serotonin in the brain, and the utility 
of tryptophan for both research and clinical 
purposes.
Pharmacokinetics
Tryptophan is the sole precursor of serotonin
35 and, 
once consumed, tryptophan is distributed through-
out the human body in the circulatory system. 
Unlike the other 19 amino acids, approximately 
75% to 85%
3,65 of circulating tryptophan is bound 
to albumin, with some estimates as high as 95%.
66 
It is primarily the non-bound, free tryptophan that 
is available for transport across the blood-brain 
barrier.
3,5,35,66–68 However, since tryptophan has a 
higher afﬁ  nity for the blood-brain barrier (BBB) 
transporter than it does for albumin,
3–69,70 albumin-
bound tryptophan that is in close proximity to the 
BBB will likely dissociate from the albumin to be 
taken up into the brain.
3 Because of this difference 
in afﬁ  nity, some researchers have concluded that 
up to 75% of albumin-bound tryptophan may be 
available to cross the blood-brain barrier.
3 In the 
bloodstream, tryptophan competes with other large 48
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neutral amino acids (LNAA; e.g. histidine, 
isoleucine, leucine, methionine, phenylalanine, 
threonine, tyrosine, and valine) for the BBB trans-
porter.
3,35,36,71,72 Given that BBB transporter is 
nearly saturated at normal plasma concentrations 
of amino acids, it is uniquely susceptible to com-
petitive inhibition.
73 Because of the competitive 
transport among the LNAAs, the bioavailability of 
tryptophan for transport across the BBB is best 
expressed by the ratio of tryptophan to the sum of 
its competing amino acids.
9,36,66,74 Therefore, 
changing the ratio of tryptophan to the other 
competing large neutral amino acids can 
signiﬁ  cantly affect concentrations of brain trypto-
phan available for serotonin synthesis. This can be 
accomplished by changing plasma concentrations 
of tryptophan, or by changing concentrations of 
the CAAs, either of which affect tryptophan 
availability and, by extension, serotonin 
synthesis.
75–78 Although other inﬂ  uences, such as 
stress, insulin resistance, magnesium or vitamin 
B6 deﬁ  ciency, and increasing age, can affect the 
rate of serotonin synthesis,
79 ﬂ  uctuations in the 
tryptophan/CAA ratio and changing tryptophan 
availability are the two factors most likely to affect 
this process.
To some extent, tryptophan availability to the 
brain can be enhanced by ingestion of carbohydrates 
and reduced by ingestion of proteins. Carbohydrate 
ingestion does not change the levels of circulating 
tryptophan, but it does decrease concentrations of 
CAAs through activation of insulin,
3,5 which 
increases the relative availability of tryptophan for 
transport into the brain.
5,66,80,81 In contrast, protein 
contains relatively low concentrations of tryptophan 
and ingestion of a protein meal increases the CAA 
concentration relative to tryptophan.
5,66 The result 
is a larger percentage of circulating CAAs, which 
increases the competitive advantage over trypto-
phan for crossing the blood-brain barrier. This 
advantage is reﬂ  ected in a smaller tryptophan/CAA 
ratio.
5,66,81,82 Therefore, the ingestion of carbohy-
drates or proteins has the potential to change the 
availability of tryptophan for synthesis of brain 
serotonin; however, even small amounts of protein 
(as little at 4%) in a carbohydrate meal can prevent 
the increase in the tryptophan/CAA ratio.
The ability of carbohydrate and protein meals 
to modify tryptophan availability may be depen-
dent on the time of ingestion.
83,84 In one study, 
comparison of three calorically equivalent high 
carbohydrate meals across the day showed an 
elevated tryptophan/CAA ratio only after the ﬁ  rst 
meal of the day.
83 Another study
85 showed that 
evening meals comprised of either 20% protein or 
500 kcal carbohydrates had no signiﬁ  cant effect 
on the tryptophan/CAA ratio. In contrast, a subse-
quent study administered a standard breakfast at 
8 AM and a test lunch administered 4 hours later. 
Results showed that a “starch” (63% carbohy-
drates) or “sucrose” (73% carbohydrates) test lunch 
signiﬁ  cantly increased the tryptophan/CAA ratio 
for the next 5 hours, while a lunch of protein (47% 
protein) signiﬁ  cantly decreased the ratio for the 
next 4 hours.
82 However, the former two studies 
used energy equivalent meals while the latter did 
not, which may be the source of the discrepant 
results. The breakfast in the latter study was com-
prised of 220 kcal, whereas the starch and sucrose 
test meals were 632 and 672 kcal (respectively) 
and the protein meal was 615 kcal. When taken 
together, the ﬁ  ndings from these studies suggest 
that changes in tryptophan availability can be 
manipulated to some extent through dietary intake, 
although it is unlikely that ordinary changes in 
dietary tryptophan or the CAAs through protein or 
carbohydrate manipulations will produce changes 
substantial enough to have a noticeable impact on 
behavior in a healthy individual.
5,86
In addition to these dietary factors that affect 
tryptophan’s availability for synthesis of brain 
serotonin, acute alcohol consumption has also been 
shown to decrease the tryptophan/CAA ratio by 
about 10% at about 30 minutes and 20%–25% at 
about 1.5 to 2 hours following ingestion.
87,88 This 
decrease suggests that brain serotonin synthesis is 
impaired under these conditions.
87,89 Where the 
average individual is likely to tolerate this level of 
serotonin depletion without undue effects on 
their behavior, vulnerable individuals may experi-
ence a larger depletion effect (e.g. 50% or 
more).
90,91 This vulnerability may be due to a pre-
existing condition of low or borderline serotonin 
function that could be further impaired by the 
diminished serotonin synthesis following acute 
alcohol consumption.
88,89
Research Methodologies 
of Tryptophan Manipulation
While there are a number of methodologies used 
to study serotonin dysregulation, one of the most 
widely used methods is to reduce brain serotonin 
synthesis, typically by reduction of tryptophan 49
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availability. Experimental manipulations of 
tryptophan are dependent on the two-step process 
required for serotonin synthesis in the brain.
35 First, 
brain tryptophan is converted to 5-hydroxytryptophan 
by the tryptophan hydroxylase enzyme (the rate-
limiting step of serotonin synthesis). Second, 
5-hydroxytryptophan is converted to serotonin by 
the aromatic amino acid decarboxylase enzyme. It 
is the activity of tryptophan hydroxylase that is 
dependent on the availability of brain trypto-
phan.
9,35–37,66 Because tryptophan hydroxylase is 
typically 50% saturated with its tryptophan sub-
strate, an increase or decrease of tryptophan avail-
ability in the brain can increase or decrease brain 
serotonin synthesis.
34,37,78,88,92–94 Tryptophan 
hydroxylase is also dependent on oxygen
95 and 
tetrahydrobiopterin
96 as cofactors that regulate its 
enzymatic activity.
The ability to change the rates of serotonin 
synthesis is the foundation of a large body of 
research examining the relationship of serotonin 
dysregulation to mood, behavior, and cognition. 
One experimental method that has been used for 
studying the effects of decreased serotonin synthe-
sis is the use of parachlorophenylalanine (PCPA).
66 
Also known as fenclonine, PCPA is a synthetic 
amino acid that is a selective inhibitor of tryptophan 
hydroxylase and found to cause a nearly complete 
and irreversible inactivation of tryptophan hydrox-
ylase activity in studies of rat brain.
97,98 However, 
in the rat, as PCPA is metabolized over time, the 
blockade is eventually reversed as new tryptophan 
hydroxylase is synthesized.
97 Early studies of the 
relationship between serotonin and depression used 
this approach to block serotonin synthesis.
99–101 
While this method produced clear reductions in 
serotonin synthesis, it was not pursued in human 
research due to a number of negative side effects, 
including the potential for allergic eosinophilia.
66 
Another method for examining the effects of 
reduced serotonin synthesis is to experimentally 
restrict dietary intake of tryptophan, which slowly 
reduces tryptophan availability. However, this 
method is limited by a relatively lengthy period of 
dietary restrictions (e.g. up to 10 days), which have 
shown only 15% to 20% reductions of the plasma 
total tryptophan with minimal behavioral or 
neurochemical effects in humans.
5,66,86
Acute tryptophan depletion and loading
Much more pronounced reductions of plasma 
tryptophan can be obtained using the acute 
tryptophan depletion methodology, which produces 
maximal (but transient) tryptophan depletion 
within 5 to 6 hours. This method typically involves 
the administration of an amino-acid beverage that 
contains approximately 100 g of 15 amino acids 
(see Table 2), but lacks tryptophan.
66,77,102 Con-
sumption of this beverage results in two separate 
processes that reduce the availability of tryptophan 
for crossing the blood-brain barrier. First, the intake 
of the large amount of amino acids stimulates 
protein synthesis in the liver; however, without a 
proportionate intake of tryptophan, the protein 
synthesis clearly reduces the concentration of 
existing plasma tryptophan.
9,25,26,35–37,66,103 Second, 
the small amount of plasma tryptophan relative to 
the high concentration of plasma CAAs further 
decreases the availability of tryptophan for crossing 
the blood-brain barrier. Both ongoing protein 
synthesis and a lower plasma tryptophan/CAA ratio 
maximize the competitive disadvantage for tryp-
tophan transport into the brain.
36,77 This two-fold 
Table 2. Amino acid compositions of 50 g and 100 g 
L-tryptophan depletion and loading formulations.
L-tryptophan Formulation 50 g 100 g
L-tryptophan Depletion 0.00 0.00
*
‡○L-tryptophan Loading 5.15 10.30
15 Amino Acids
L-alanine 2.75 5.50
L-arginine 2.45 4.90
*L-cysteine 1.35 2.70
Glycine hydromonochloride 1.60 3.20
*L-histidine 1.60 3.20
*
‡○L-isoleucine 4.00 8.00
*
‡○L-leucine 6.75 13.50
○L-lysine 4.45 8.90
*
○L-methionine 1.50 3.00
*
‡○L-phenylalanine 2.85 5.70
L-proline 6.10 12.20
L-serine 3.45 6.90
*
○L-threonine 3.25 6.50
*
‡○L-tyrosine 3.45 6.90
*
‡○L-valine 4.45 8.90
Depletion, total grams 50.00 100.00
Loading, total grams 55.15 110.30
*Competing amino acids (CAA); 
‡CAAs typically summed for 
calculating the tryptophan/CAA ratio; 
○Essential amino acids.50
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effect results in a signiﬁ  cant decrease of brain 
serotonin synthesis in both human and non-human 
primates,
77,78,104,105 and studies of rat brain have 
also shown reductions of neuronal serotonin 
release.
66,106,107 Conversely, serotonin synthesis can 
be increased using acute tryptophan loading, which 
is often used as a control condition for depletion. 
Tryptophan loading is accomplished by adding a 
disproportionately large amount of tryptophan to 
the amino-acid formulation. This large amount of 
tryptophan maximizes tryptophan’s competitive 
advantage and increases the availability of 
tryptophan for brain serotonin synthesis.
37 The 
speciﬁ  city of tryptophan depletion appears to be 
established by comparing this formulation with an 
alternative formulation designed to deplete lysine 
(an arbitrarily chosen essential amino acid). Mood 
and memory effects were speciﬁ  c to tryptophan 
depletion, which would seem to rule out general 
inhibition of protein synthesis that would also 
likely impair mood and memory functions. 
Moreover, when compared to control conditions 
(e.g. tryptophan loading or a balanced formulation), 
effects are speciﬁ  c to the depletion.
32,37,108–111
Effectiveness of tryptophan 
manipulations
Using both tryptophan depletion and loading, many 
studies have provided measures of the effectiveness 
of these manipulations for changing plasma 
tryptophan. A comparison across studies showed 
an 81% average reduction of plasma tryptophan 
following consumption of the most commonly used 
100 g depletion formulation,
112 with reductions 
ranging from 55% to 94%.
27,37,77,88,102,104,112–117 
Comparable results have been found following 
administration of a 50 g (i.e. half-size) formulation. 
For example, relative to pre-drink measures, two 
time-course studies showed robust depletions of 
87% (i.e. free and total tryptophan;)
112 and 89% 
(i.e. free tryptophan/CAA ratio;)
37 maximal reduc-
tion of plasma tryptophan following consumption 
of the 50 g depletion formulation. Likewise, the 
50 g and 100 g tryptophan loading formulations 
have also shown similar results, both of which 
produce marked increases in plasma tryptophan 
that range from 300% to 500% of pre-drink 
measures.
37
A potential limitation of this methodology is 
that reductions of serotonin synthesis may not be 
uniform across all brain areas and may not be 
representative of neuronal release. However, 
positron emission tomography (PET) following 
tryptophan depletion showed reductions of sero-
tonin synthesis were similar across multiple areas 
of the brain in spite of differences in the density of 
innervations,
78 although speciﬁ  c areas affected 
may vary by sex.
118 Furthermore, results from 
several rodent studies have provided supporting 
evidence that neuronal release of serotonin occurs 
in direct relationship to the concentration of its 
tryptophan substrate,
119–122 however one rodent 
study indicated that physiological variables other 
than substrate availability may be of greater impor-
tance for regulating serotonin synthesis and 
release.
123,124 Similarly, a recent rodent study 
examined the relationship between dietary trypto-
phan depletion and concentrations of extracellular 
serotonin. Plasma tryptophan was depleted by 
70%, but microdialysis results showed no corre-
sponding reductions of extracellular serotonin.
125
Methodological considerations
When designing research protocols to investigate 
various mood, behavior, or cognitive effects of this 
methodology, it is important to consider that the 
onset and duration of the peak change in plasma 
indicators of brain serotonin synthesis likely do 
not coincide with serotonergic changes in the brain, 
which may affect the experimental design. 
However, it is possible to infer both the onset and 
duration of signiﬁ  cant changes in brain serotonin 
concentrations and function following tryptophan 
manipulations from studies that have concurrently 
measured both plasma tryptophan and central 
indicators (e.g. lumbar punctures measuring cere-
brospinal ﬂ  uid tryptophan or the primary metabo-
lite of serotonin, 5-hydroxyindoleacetic acid) of 
changes in serotonin catabolism. Two previous 
studies have shown that these central measures 
reached their lowest point approximately two hours 
after the onset of the maximal changes of plasma 
tryptophan measures for both the 50 g
112 and 
100 g
104 depletion formulations, and noted that this 
extended estimate does not account for time 
between brain changes and measurements taken at 
the lower end of the spinal column.
112 Furthermore, 
a PET scan of the human brain indicated signiﬁ  cant 
changes in serotonin synthesis occurred at 5 hours 
following amino acid consumption.
78 Depending 
on the size of the drink (e.g. 50 g or 100 g) and the 
plasma measure used (e.g. total tryptophan or free 
tryptophan to competing amino acids), near 51
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maximal reductions of plasma measures remain 
for another 4 to 5 hours following onset (i.e. up to 
8 to 10 hours following administration),
37,104,112 
which provides sufﬁ  cient overlap for an optimal 
testing window at 6 to 7 hours following amino 
acid consumption.
Relative to the other methods for experimentally 
reducing brain serotonin synthesis (i.e. enzyme 
inhibitors and dietary manipulations), using acute 
tryptophan depletion and loading amino-acid 
formulations presents some signiﬁ  cant advantages. 
These amino-acid manipulations are economical, 
safe, and minimally invasive, as well as highly 
effective for rapidly producing substantial changes 
in tryptophan availability to the brain. These effects 
are also transient and quickly reversed by returning 
to a normal diet.
126 Furthermore, manipulating the 
underlying biology prior to testing also provides 
for interpretations of cause and effect relationships. 
For these reasons, acute tryptophan depletion has 
remained an important and popular research tool 
for understanding serotonergic dysregulation.
Research Applications of Acute 
Tryptophan Depletion
Acute changes in tryptophan availability have been 
used to test a wide variety of basic psychological, 
behavioral, and physical processes,
66,127 including: 
motion sickness,
128 sleep,
129,130 mood,
27,77 visual 
discrimination,
30 cognition,
34 social information 
processing,
33 and memory processes.
31,32 This 
method has also been applied in investigations of 
numerous psychiatric disorders, including: Major 
Depressive Disorder,
131 Seasonal Affective 
Disorder,
132,133 Bipolar Disorder,
134,135 Obsessive-
Compulsive Disorder,
136 Schizophrenia,
137 Bulimia 
Nervosa,
115 Premenstrual Syndrome,
138 and Panic 
Disorder.
139 While this is a widely-used technique, 
the majority of this research has been more 
specifically focused on mood and depression, 
memory and other cognitive functions, and 
behavior. 
Mood and depression
One of the earliest and most common uses of tryp-
tophan depletion was for the study of changes in 
mood which are commonly believed to be related 
to serotonergic mechanisms. Some of the earliest 
studies found modest mood-lowering effects 
following acute tryptophan depletion in samples 
of healthy young men.
102 Since then, results have 
varied considerably, such that approximately half 
of published studies have found no effects on mood 
in healthy adult samples.
102,140 A number of these 
studies have reported that healthy women may be 
more vulnerable to the mood-lowering effects of 
tryptophan depletion than men,
138,113,141,142 which 
is supported by imaging studies that provide 
evidence of sex differences in brain serotonin 
synthesis.
78,118 The differences found between men 
and women are also consistent with the general 
consensus that conﬂ  icting ﬁ  ndings appear to be the 
result of characteristic differences in the individuals 
being tested.
103,126 For example, positive results 
have involved individuals with baseline depression 
scores at the upper end of normal, while negative 
results have generally been found in those with 
lower baseline scores.
126,143,144 The lack of effect 
on mood following tryptophan depletion in 
rigorously screened healthy individuals (e.g. low 
baseline depression, aggression, or impulsivity 
scores) is supported by a similar lack of effect 
found in imaging studies (e.g. fMRI, PET).
145
The extent of the effects of acute tryptophan 
depletion on mood appears to be related to varying 
levels of vulnerability to disturbance of the central 
serotonin system. Relative to healthy controls, 
there is more consistency of mood-lowering effects 
in healthy adults who may be vulnerable to 
serotonin disturbances, such as those with family 
histories of mood disorders
16,32,135,146,147 or other 
underlying biological vulnerabilities (e.g. genetic 
or brain abnormalities).
148,149 The most consistent 
effects on transient changes in mood states have 
been found in patients with remitted depression 
who are concurrently receiving antidepressant 
treatment. In 8 out of 10 studies, tryptophan 
depletion produced a temporary return of clinical 
symptoms in patients who were responsive to their 
treatments.
126 Two prospective studies have also 
reported that the tryptophan depletion methodology 
may be a useful predictor of future depressive 
episodes. These studies administered tryptophan 
depletion to symptom-free, treatment-free 
individuals with a history of either a major depres-
sive episode
150 or seasonal affective disorder,
132 
and followed the individuals for up to one year. 
Results from both studies indicated that the indi-
viduals who responded with depressive symptoms 
during tryptophan depletion were at greater risk 
for subsequent depressive episodes than 
non-responders. In summary, these results suggest 
that serotonin dysfunction is a trait abnormality in 52
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depressive disorders,
144 and that individuals with 
a particular biological vulnerability for future 
depression may be especially sensitive to even 
transient changes in serotonin availability.
150
Cognitive processes
In contrast to the typical lack of mood changes in 
healthy adults, tryptophan depletion has been 
demonstrated to affect a variety of cognitive 
processes in both healthy individuals and those 
with a serotonergic vulnerability. Impairments in 
a variety of learning and memory skills following 
tryptophan depletion are well documented. The 
most reliable ﬁ  ndings are impairments of declarative 
episodic memory processes of delayed recall and 
memory consolidation.
151 For example, in healthy 
adults, when a word list was learned at 6 hours 
after tryptophan depletion (i.e. during peak effect) 
and active recall was tested 30 minutes later, both 
recall and word recognition were impaired; 
however, when tested immediately following 
presentation of the word list, no effect was found.
152 
Riedel and colleagues concluded that compromised 
serotonergic activity impaired consolidation of 
information into long-term memory without any 
effect on short-term memory. These long-term 
memory deficits in delayed recall have been 
replicated in numerous studies using a variety of 
presentations, including visual and auditory 
presentation of words, as well as presentation of 
pictures and abstract shapes (for detailed reviews, 
see
151,153). These effects have been found in healthy 
adult volunteers,
31,154–156 in adults with a family 
history of bipolar disorder,
157 and in clinical 
samples.
158,159 For instance, in a comparison of 
adults with and without family histories of bipolar 
disorder, tryptophan depletion impaired long-term 
memory consolidation in both groups, and problem 
solving was also impaired in those with a family 
history, while problem solving improved in those 
without a family history.
32
Tryptophan depletion has also been shown to 
impair learning on visual discrimination and 
memory retrieval,
114 episodic memory,
155 stimulus-
reward learning,
30 and cognitive flexibility,
160 
among other cognitive processes, although more 
studies are needed to test the reliability of these 
results. In an editorial commentary on cognitive 
effects of tryptophan depletion, Riedel
161 notes that 
there are a number of other physiological effects 
that may result from tryptophan manipulations that 
could be involved in the modulation of cognitive 
functions, such as quinolinic acid (NMDA agonist), 
and kynurenic acid (NMDA, nicotinic, and 
glutamatergic antagonist), which should also be 
considered for measurement.
42 
Behavior
Finally, tryptophan manipulations have a long history 
of studying behavior using laboratory-measures to 
assess social behavior and changes in aggression and 
impulsivity that may be dependent, in part, on 
changes of serotonin synthesis.
30,36,88,162–166 For 
example, laboratory-measured aggression (i.e. Point 
Subtraction Aggression Paradigm, PSAP;)
110,111 was 
shown to increase following tryptophan depletion, 
and this effect was greater in those that responded 
more aggressively before the manipulation.
111 
Additionally, following tryptophan depletion, men 
who reported high-trait aggression have shown 
increased laboratory aggressive behavior relative 
to low-trait aggressive men.
108 Interestingly, among 
women, tryptophan depletion increased laboratory-
measured aggression (i.e. PSAP) while tryptophan 
loading decreased aggression and this effect was 
speciﬁ  c to those women with elevated plasma 
tryptophan at baseline.
36 This ﬁ  nding was sup-
ported by a study of healthy adult men and women 
who completed a number of measures of self-
reported anger, hostility, and aggression that were 
related to their endogenous plasma tryptophan 
levels.
167 Results showed that higher tryptophan 
levels were associated with elevated anger, hostil-
ity, and aggression scores in women, but not men. 
As noted in the previous study, this association was 
speciﬁ  c to women with elevated plasma trypto-
phan, compared to women with lower plasma 
tryptophan levels who were more agreeable, less 
hostile, and less likely to express their anger.
Both animal and human studies have shown that 
serotonin function is involved in inhibitory control 
of aggression.
168–170 While reduced serotonergic 
functioning has been clearly associated with aggres-
sive and violent behavior in general,
171,172 it is more 
speciﬁ  cally related to impulsive aggression
168,170 
and likely to be involved in modulating inhibitory 
behavior and expression of impulsivity.
171,172 This 
was demonstrated in a study of aggressive adoles-
cents with Attention Deﬁ  cit Hyperactivity Disorder 
(ADHD) where laboratory-measured impulsive 
aggression was increased following tryptophan 
depletion relative to a balanced control, and this 53
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effect was independent of age and intensity of 
ADHD symptoms.
173 Similarly, in a sample of 
aggressive adolescent males, impulsivity was 
elevated compared to nonaggressives, but this 
elevation was the same with and without tryptophan 
depletion,
172 although the authors suggest this was 
most likely due to a ceiling effect . In another study 
of young men with and without a family history of 
paternal alcoholism, tryptophan depletion showed 
no effect on aggressive responses during a modiﬁ  ed 
Taylor aggression task in either group. However, 
increased disinhibition (on a go/no-go task) was 
demonstrated by the men with a family history of 
alcoholism relative to both placebo and men with-
out a family history.
164 These authors concluded 
that there are subsets of individuals who appear to 
be more vulnerable to serotonergic dysregulation 
and impulsive behavior. A recent examination of 
whether serotonin modulates impulsive behavior 
through mechanisms involved in emotion used 
tryptophan depletion and placebo control to test a 
laboratory model of self-regulation.
166 Contrary to 
other results, reduced serotonin function increased 
the retaliation to perceived unfairness without 
changing response inhibition, mood, or reward 
processing. These divergent ﬁ  ndings may be the 
result of methodological differences of testing 
paradigms that examine different underlying 
mechanisms,
174 and/or these results may represent 
differences among the volunteer testing samples. 
Future studies that use multiple behavioral mea-
sures in the same experimental sample may clarify 
these conﬂ  icting ﬁ  ndings.
174
When examining the relationship of trait 
impulsivity to changes following tryptophan 
depletion, boys with ADHD were divided into high 
and low trait impulsivity groups. Using a competitive 
reaction time test, tryptophan depletion increased 
impulsive aggression of the low impulsive group, 
but not the high impulsive group.
175 The authors 
suggested that the lack of effect in the high impul-
sive group was likely due to the difficulty of 
increasing already high rates of impulsivity that 
could not be further influenced by reduced 
serotonin, whereas the depletion effect could make 
the low impulsive group react as if they were high 
impulsive. Additionally, using a continuous 
performance test in normal healthy men, trypto-
phan depletion produced increased laboratory-
measured impulsivity compared to placebo.
176 
Other studies, using stop-signal tasks have failed 
to find increased impulsive responding after 
tryptophan depletion.
177,178 Using a stop-signal 
task, another group tested behavioral inhibition 
and learning using a selective serotonin reuptake 
inhibitor and a selective noradrenaline reuptake 
inhibitor, both known to rapidly increase brain 
serotonin and noradrenalin (respectively) in animal 
testing.
179 Results indicated that increased 
noradrenaline improved inhibitory responding, but 
serotonin had no effect. Rather, increased serotonin 
impaired learning, whereas noradrenaline had no 
effect. This difference between continuous perfor-
mance and stop-signal tasks may signify different 
underlying behavioral mechanisms governing 
these responses.
A recent review of brain activation in imaging 
studies (i.e. fMRI, PET)
179 examined results 
from studies using a variety of cognitive tasks 
(e.g. response inhibition, learning, response 
interference, verbal ﬂ  uency). The authors concluded 
that overall, results appear to indicate involvement 
of serotonin dysregulation in cognitive impair-
ments, but the number of divergent results remains 
puzzling. Contrary ﬁ  ndings from different studies 
may be the result of a variety of explanations and 
a host of methodological differences, including use 
of tasks that measure different underlying processes 
and testing samples of individuals who differ in 
personality, gender, family histories, and genetic 
vulnerabilities. While serotonin plays a part in 
cognitive functions, inconsistencies across studies 
need to be addressed in the future both to control 
for, and study, interindividual differences.
Therapeutic Uses of Tryptophan
While dietary intake alone (i.e. ingestion of food) 
would seldom inﬂ  uence the availability of trypto-
phan signiﬁ  cantly, administration of exogenous 
tryptophan has been the focus of numerous clinical 
research and homeopathic applications. One of the 
earliest examples was an attempt by Lauer and col-
leagues
180 to augment treatment response for 
schizophrenia by combining tryptophan administra-
tion with iproniazid, a monoamine oxidase inhibi-
tor (MAOI). The success of the combined treatment 
compared to the MAOI alone changed how 
researchers thought about the inﬂ  uence of trypto-
phan treatment on brain function,
84 and began a 
series of clinical trials testing the efﬁ  cacy of treat-
ment for a number of clinical disorders that yielded 
promising but often inconclusive results. Trypto-
phan has been used for a broad spectrum of clinical 54
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applications, such as treatment of pain, insomnia, 
depression, seasonal affective disorder, bulimia, 
premenstrual dysphoric disorder, attention deﬁ  cit/
hyperactivity disorder, and chronic fatigue (see
17,84). 
Tryptophan has also been widely used as an over-
the-counter, natural remedy for depression, pain, 
insomnia, hyperactivity, and eating disorders.
17
The therapeutic use of tryptophan for treatment 
of clinical disorders and syndromes has concen-
trated primarily on increasing tryptophan intake for 
the treatment of depressive disorders and related 
conditions, although other psychiatric and medical 
conditions appear to be somewhat responsive to 
tryptophan treatment. One of the most frequent 
clinical uses of tryptophan has been for the treatment 
of major depression; however, clinical ﬁ  ndings of 
the efﬁ  cacy of tryptophan treatments are mixed.
Depression
Tryptophan has been found to be as effective as 
tricyclic antidepressants in a number of trials,
181–183 
and one study found that the effects of tryptophan 
and amitriptyline, alone and in combination, were 
all superior to placebo.
184 However, other studies 
with tricyclic antidepressants have shown 
inconsistent efficacy for treating depressive 
symptoms.
184–187
Studies of tryptophan in combination with elec-
troconvulsive therapy (ECT) have also produced 
inconsistent ﬁ  ndings. One study demonstrated that 
patients with depression who received combined 
doses of tryptophan (3 g/day) and nicotinamide for 
4 weeks reported signiﬁ  cantly lower ratings of 
depression compared to those who received ECT 
twice weekly.
188 Conversely, in another study, 
patients with a severe primary depressive illness 
treated with ECT improved signiﬁ  cantly compared 
to those receiving tryptophan (6 to 8 g) plus 
pyridoxine daily.
189 Similarly, patients receiving 
ECT twice daily improved signiﬁ  cantly compared 
to patients receiving daily doses of combined 
tryptophan (6 g) and pyridoxine.
190 In yet another 
study, there were no signiﬁ  cant differences in 
depressed patients treated with tryptophan alone 
(6 g/day) compared to ECT alone.
191
In contrast to the mixed results of the effects of 
tryptophan with tricyclic antidepressants or ECT, 
tryptophan has been shown to be more effective in 
combination with monoamine oxidase inhibitors 
(MAOI). For example, depressed patients who 
were unresponsive to a 60 mg/day dose of the 
MAOI phenelzine received supplements of 12, 15, 
or 18 g of tryptophan or placebo. A signiﬁ  cantly 
higher percentage of the patients on the combined 
therapy (i.e. MAOI plus tryptophan) improved 
compared to those receiving the MAOI alone or 
with placebo.
192 Patients who received a combined 
therapy of tryptophan (6 g/day) and a different 
MAOI, nialamide, also improved signiﬁ  cantly 
compared to those who received nialamide alone.
185 
In another study, compared to patients who 
received doses of the MAOI tranylcypromine plus 
placebo for one week, those who received a 
214 mg/kg/day supplement of tryptophan reported 
a signiﬁ  cant decrease in depression ratings during 
that week, as well as during the 2 weeks after 
tryptophan supplements were discontinued.
193
Although the results of the therapeutic combina-
tion of tryptophan with MAOIs have demonstrated 
the most successful results for treatment of 
depression, most clinical studies have produced 
mixed results as to the efﬁ  cacy of tryptophan for 
treatment of depression. These mixed results are 
due, in part, to ﬂ  awed study designs and trials using 
insufﬁ  cient lengths of time to allow determination 
of efﬁ  cacy. Methodological differences such as 
inconsistent diagnostics within and across studies
43 
have also produced mixed results. Taken together, 
there is evidence that tryptophan is effective for 
ameliorating mild to moderate depressive symp-
toms, but not severe depressive symptoms.
84
Other mood disorders
Tryptophan has been used successfully in the 
treatment of seasonal affective disorder and may 
be as effective as light therapy. In one open-label 
study, 16 patients who met DSM-IV criteria for a 
recurrent major depressive disorder with a seasonal 
(winter) pattern were treated with light therapy for 
2 weeks. The treatment for those who were partial 
or non-responders to this light therapy was then 
augmented with tryptophan (3 g/day) for 2 weeks, 
which produced a marked response to treatment.
28 
In a second study, patients who met criteria for 
major depression with a seasonal pattern were 
treated with combined light therapy and tryptophan. 
Half received 2 weeks of light therapy ﬁ  rst and the 
other half received 4 weeks of tryptophan treatment 
ﬁ  rst (with a 1-week washout between treatments). 
While one third of the patients showed no response 
to either treatment, over half of the patients showed 
signiﬁ  cant improvement during both treatments 
regardless of the order of treatment.
2955
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Steinberg and colleagues conducted a random-
ized, double-blind, placebo-controlled trial to 
assess the efﬁ  cacy of tryptophan (6 g/day) for treat-
ing Premenstrual Dysphoric Disorder symptoms.
194 
Those patients receiving tryptophan reported 
signiﬁ  cant reductions in dysphoria, mood swings, 
and irritability compared with those receiving 
placebo. These effects were thought to be the result 
of increased kynurenine synthesis during the 
late-luteal phase of the menstrual cycle.
195 
Sleep disorders
Tryptophan has also been used for the treatment 
of sleep disorders, and is thought to produce its 
therapeutic effects through melatonin mechanisms. 
Improvement in sleep latency has been reported
196,197 
with doses as low as 1 g,
198 and improved Stage IV 
sleep has been reported with doses as low as 
250 mg.
198 An important feature of tryptophan 
treatment is that, unlike many other medications 
administered for sleep disorders, it does not limit 
cognitive performance or inhibit arousal from 
sleep.
197,199 Tryptophan also produces signiﬁ  cant 
improvements in obstructive sleep apnea, but not 
central sleep apnea.
200 After an average dose of 
2.5 mg of tryptophan administered at bedtime, 
patients with obstructive sleep apnea showed 
signiﬁ  cant improvement while those with central 
sleep apnea did not.
Other uses
In patients undergoing smoking cessation, trypto-
phan (50 mg/kg/day) has been used in combination 
with a high carbohydrate diet, and is reported to 
reduce anxiety and severity of withdrawal symp-
toms, and to improve abstinence or reduce the 
number of cigarettes smoked.
201 However, trypto-
phan treatment has been reported to have no effect 
on bruxism
202 and, in combination with dietary 
manipulations, tryptophan treatment has also shown 
no effect on chronic myofascial pain.
203
Conclusions
In summary, tryptophan is a unique amino acid that 
is an essential component of the human diet. 
Although it has the lowest concentration in the 
human body relative to the other 19 primary amino 
acids, tryptophan is a critical component of 
numerous metabolic functions. Despite the side 
effects noted above and past concerns about the 
safety of tryptophan as a treatment or nutritional 
supplement, tryptophan has been widely used in 
numerous research and clinical trials without 
incident for nearly 25 years e.g.
9,32,36,37,64,66,88,103,11
1,131,141,195,204 Experimental research has shown that 
tryptophan can be an important determinant of 
mood, cognition, and behavior. Although results 
have been inconsistent, clinical trials have provided 
some initial evidence of tryptophan’s efﬁ  cacy for 
treatment of psychiatric disorders, particularly when 
used in combination with other therapeutic agents.
To improve the utility of tryptophan research for 
understanding the relationship of serotonin dys-
regulation as an underlying mechanism in psychi-
atric disorders, as well as behavioral, cognitive, and 
physical problems, it will be important to under-
stand the factors that have contributed to the incon-
sistent results from previous studies. To advance 
the efﬁ  cacy and utility of tryptophan for therapeu-
tic purposes, future clinical studies will need to 
improve on methodological pitfalls made in the 
past. Such considerations would include employing 
systematic control of dosing, standardization of 
both research and treatment methodologies, and 
improved diagnostics of psychiatric disorders to 
test more homogeneous groups of patients, as well 
as careful selection and matching of patient and 
control groups (or conditions) being tested.
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